RecruitingNot ApplicableNCT05431296

Glucose Monitoring After Acute Myocardial Infarct in People With Diabetes

Sponsor

Imperial College London

Enrollment

160 participants

Start Date

Feb 7, 2023

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes Acute Myocardial Infarction Acute Myocardial Infarction With ST Elevation Diabetes Complications

Summary

Glucose monitoring after Acute Myocardial infarct in people with diabetes is a Dexcom funded study that is investigating whether the use of continuous glucose monitors (Dexcom ONE model) in people with type 2 diabetes facilitates time in glycaemic range in the 6 months after an acute myocardial infarction. As an exploratory outcome it will investigate whether time in glycaemic range is associated with changes in mortality and major adverse cardiac events in the 6 months after acute myocardial infarct.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how well continuous glucose monitors (CGMs) — small wearable devices that track blood sugar in real time — help manage blood sugar levels in people with type 2 diabetes who have had a heart attack or serious heart event. The goal is to see if CGMs lead to better blood sugar control and fewer complications. **You may be eligible if:** - You are over 18 years old - You have type 2 diabetes (diagnosed before or during your hospital stay) - You are taking at least one diabetes medication (pill, injection, or insulin) - You were admitted to hospital with a serious heart event (such as a heart attack), OR you previously had a heart attack within the last 10 years **You may NOT be eligible if:** - Your blood sugar has been well controlled (HbA1c below a certain level, indicating diabetes may not be established) - You have previously had weight loss (bariatric) surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEDexcom ONE Continuous Glucose Monitoring System

The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.